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Recently, IgE molecules have been demonstrated on Langerhans cells (LC) from
involved and, to a much lesser extent, in uninvolved skin of patients with atopic der-
matitis, but not on LC from nonatopic individuals (1, 2). This finding indicated
that, in atopic dermatitis, LC are induced to either synthesizereceptors for IgE and/or
to acquire IgE-binding FceR2 split products. As opposed to the selective expression
of FcER1 by basophils and mast cells, low affinity Fc-IgE receptors (FceR2/CD23)
have been described on numerous cell types including B and T cells, eosinophils,
platelets, and monocytes (3, 4). The most recent finding that an anti-FceR2 mAb
can inhibit the binding of IgE-coated ox erythrocytes to LC from atopic dermatitis
patients (5) supports the contention that the presence of IgE on LC surfaces in this
disease results from the binding of IgE to FceR2 . For many of the above cells,
FceR2/CD23 expression is not a constitutive event but rather regulated by soluble
mediators including human rIL-4 (hrIL-4; 6, 7), human rIFN-y (hrIFN-y; 6, 8),
and PMA (8).
To establish an in vitro model for studying putative T lymphocyte-LC interac-
tions in atopic dermatitis, we asked in this study whether these substances can in-
duce FceR2/CD23 expression on LC isolated from the epidermis of nonatopic indi-
viduals and, if so, whether such LC are capable of IgE binding.
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Reagents.
￿
mAbs against CDla antigen (phycoerythrin [PE]-labeled T6/RDI, IgGI, Coulter-
tronics, Krefeld, FRG; FITC-labeled OKT6, IgGI, Orthopharmaceuticals, Raritan, NJ) were
used for LC labeling (9). M-L25 (IgGI; Institute for Immunology, Munich, FRG) (10) and
3-5 (IgGl; kindly provided by T. Kishimoto, Institute of Molecular and Cellular Biology,
University of Osaka, Japan) (11) are both anti-CD23 mAbs. BIP-1 (IgGI; Institute ofGeneral
and Experimental Pathology, University ofVienna, Austria) (12), anti-IgM mAb AF-6 (IgGI;
Immunotech, Marseille, France), and anti-IgG mAb 8a4 (10 hg/ml) (IgGI, Immunotech,
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Marseille, France) were used forcontrol purposes. The IgE myeloma protein sha was purified
by DEAE chromatography and used at a concentration of 10 Fcg/ml. FITC-labeled goat
anti-mouse (GAM/FITC) was obtained from Grub Laboratories, Scandic, Vienna, Austria.
FITC-labeled goat anti-human IgE (GAHuIgE/FITC) was purchased from Dakopatts, Ham-
burg, FRG.
LC-enrichedHumanEpidermalCells.
￿
Cells were prepared as described elsewhere (Yokozeki,
H., A. Rieger, C. Forster, A. Binder, V. Groh, and G. Stingl, submitted for publication).
Briefly, split-thickness specimens of cadaver skin were subjected to 0.5% trypsin/PBS for 90 min
at 37'C . The loosened epidermis was then peeled off and vigorously agitated in FCS (Gibco
Laboratories, Berlin, FRG)-supplemented RPMI 1640 containing 0.01% DNase (Sigma Chem-
ical Co., St. Louis, MO). After several washes, resulting single cell suspensions were incubated
on collagen-coated petridishes, which resulted in a preferential attachmentofbasal keratino-
cytes. Based on our previous observation that differentiating keratinocytes are more suscep-
tible to osmotic shock treatment than other epidermal cells, nonadherent cells were then col-
lected by vigorous pipetting and subjected to hypotonic PBS/Aqua destillatamixture for 1 min
under mechanicalagitation. Resulting cells (viability -20%)were freed ofdead cells by Ficoll-
Hypaque density gradient centrifugation; interface cells recovered (viability >95% by trypan
blue exclusion) were collected and the quality of LC-enrichment was controlled by FITC-
OKT6. The possibility that other hematopoietic cells were substantially coenriched for by
this negative selection procedure can be excluded by our previous finding that >-98% of
CD45 ` cells in the final cell preparation coexpressed CDla antigens (Yokozeki, H., et al.,
submitted).
The FceR2/CD23' Human Monoblastic Cell Line U937
￿
The U937 cell line was donated by
H. L. Spiegelberg (Dept. ofImmunology, Scripps Clinic and Research Foundation, LaJolla,
CA). This cell line reacts with M-L25 and 3-5 (Bieber, T., unpublished data).
Cell Cultures.
￿
105 LC-enriched epidermal cells cultured for 8-48 h either in U-shaped
bottom 96-well microtiter plates or in 24-well plates (106/ml) in RPMI 1640 (Flow Labora-
tories, Meckenheim, FRG) containing 10% FCS (Gibco Laboratories), 1% antibiotics/an-
timycotics (Gibco), 2 MM L-glutamine (Gibco), 25 mM Hepes buffer (Seromed, Berlin, FRG),
5 mM sodium-pyruvate (Gibco), and 1% nonessential amino acids (Gibco).
U937 cells were grown in RPMI 1640 supplemented with 10% FCS, 1% antibiotics/an-
timycotics, and 2 MM L-glutamine (all from Gibco Laboratories).
For the FceR2/CD23 induction assay, cells were cultured in either absence or the presence
ofone orseveral ofthe following substances: hrIL-2, hrIL-4, 1-1,000 IU/ml (Genzyme Corp.,
Boston, MA); hrIFN--y, 1-1,000 IU/ml (Bender, Vienna, Austria); 2 ng/ml PMA (Sigma
Chemical Co); and 5 LM/ml cycloheximide (Sigma). As negative control experiments, the
cells were cultured in medium without exogenous cytokines.
LC Immunolabeling by Double-Marker Analysis.
￿
LC-enriched epidermal cells were first stained
with T6/RDl, then washed and reacted with ox eythrocytes coated with either M-L25 or
3-5, or as a control, with BIP-1 as described previously (13). Finally, the cells were resuspended
and analyzed for viability, surface staining, and rosette formation using a Leitz Aristoplan
fluorescence microscope. To verify the specificity of the rosette formation, an inhibition study
was carried out by incubation of the epidermal cell cultures with unlabeled M-L25 or 3-5
(20 tzg/ml) or isotype control at 4'C for 30 min. The cells were then washed twice in sup-
plemented RPMI 1640 and incubated with anti-CD23 mAb-coated erythrocytes as described
above.
Determination ofIgEBindingandFceR2/CD23 Expression on Cultured Cells.
￿
After being cultured
in the presence of cytokines, LC-enriched epidermal cells (5 x 105/ml) or U937 cells (5 x 105/
ml) were washed twice in supplemented RPMI 1640 and were then incubated for 30 min with
heat-inactivated AB serum. A small aliquot of this cell suspension was used to monitor by
immunofluorescence CD23 expression by LC using M-L25 (20 hg/ml) and GAM/FITC in a
consecutive order. A larger portion of the cultured cells was incubated with 10 Wg/ml myeloma
IgE for 45 min on ice, washed twice in PBS supplemented with 1% FCS and 0.1% sodium
azide at 4°C and then incubated with GAHuIgE/FITC (10 jig/ml) for 45 min on ice. Con-
trols included the use of GAHuIgE/FITC alone as well as F(ab')2 fragments of GAHuIgM/
FITC and GAHuIgG/FITC (all obtained from Immunotech), respectively. In other experi-BIEBER ET AL.
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ments, cellswere first incubated with M-L25 (20 Wg/ml), or for control purposes with BIP-1,
and then subsequently with myeloma IgE and GAHuIgE/FITC. After washing twice in PBS,
the cells were analyzed by a FACScan (Becton Dickinson & Co., Sunnyvale, CA). The back-
ground was determinedby the percentage ofcells stained by the IgGI isotype and GAM/FITC,
or by GAHuIgE/FITC.
Results
LC Enrichment.
￿
Using the negative selection procedure for LC enrichment (see
Materials and Methods), a starting population of 109 epidermal cells containing
0.5-2% CDla' cells results in the generation of 5-10 x 106 epidermal cells con-
taining 50-70% CDla' cells (viability 395% by trypan blue exclusion).
Induction ofAnti-FccR2/CD23 Reactivity ofLC by hrIL-4 and hrIFN-y.
￿
While LC-
enriched epidermal cells either freshly isolated or cultured in media alone did not
react with anti-CD23 reagents by either immunofluorescence or rosetting, hrIL-4
as well as hrIFN-,y led to a gradual, dose-dependent emergence of anti-CD23-reactive
cells. Double-marker analysis revealed that CD23 expression was confined to the
CDla' cells, i.e., to LC. Reactivity of LC with M-L25-coated ox erythrocytes oc-
curred in a dose-dependent fashion, whereas 10 U/ml of each cytokine resulted in
anti-CD23 reactivity of only 3 ± 1% (hrIL-4) and 2 ± 2% (hrIFN-'y) ofLC, respec-
tively, 1,000 U/ml ofhrIL-4 and hrIFN-y led to a specific anti-CD23 immunolabeling
of 15 ± 7 and 8 ± 3 % of LC, respectively (Table I). Similar results were obtained
with 3-5-coated erythrocytes under the same conditions. A combined use of varying
hrIL-4/hrIFN-y concentrations showed that, at each combination chosen, these
cytokines act synergistically on CD23 expression by LC (Table I) but only in an
additive fashion on that of U937 cells (data not shown); maximal CD23 induction
on LC was regularly seen with 1,000 U/ml ofboth cytokines. In this context, it should
be noted that the cytokine concentrations needed for the induction of CD23 antigen
on LC are either within the same range or only slightly higher than those needed
for CD23 induction of B cells and U937 cells, respectively (6, 14) . Kinetic studies
revealed that, when using each cytokine (1,000 U/ml) either alone or in combina-
TABLE I
hrIL-4 and hrIFN-y Have a Synergistical Effect on the
Induction of FccF2/CD23 on LC
LC enriched (50%) epidermal cell suspensions were stimulated with various com-
binated concentrations of hrIL-4 and hrIFN-y. After 24 h, the cultures were
assessed by double-marker analysis with T6/RD 1 and M-1,25-coated oxerythro-
cytes (mean t SE of three experiments).
hrIL-4
U/ml
Percent
0
of
1
FcER2/CD23' LC
10
using hrIFN-y
100
(U/ml)
1,000
0 0 0 2 t 2 6 ± 2 8 t 3
1 0 0 ND ND ND
10 3 t 1 ND 7 t 3 10 t 4 12 ± 3
100 11 f 3 ND 22 t 5 32 t 6 32 t 5
1,000 15 f 7 ND 25 t 6 35 t 7 47 ± 631 2
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FIGURE 1. (a and b) Flow cytom-
etry analysis ofIgE binding on
hrIL-4 and hrIFN-.y induced
FrER2/CD23* LC. LC-enriched
(50%) epidermal cell suspen-
sions were cultured for 24 h with
hrIL-4 (1,000 U/ml) and hrIFN-,y
(1,000 U/ml), then the cells were
washed and either stained with
M-L25 followed by GAM/
FITC or incubated with IgE
(sha) (10 wg/ml) followed by
GAHu-IgE/FITC and analyzed
by a FACScan (BD). (a) Anti-
CD23 staining. (b) Anti-IgE
staining. Dotted-line represents
the cut-off for isotype control.
tion, substantial CD23 expression by LC was first detectable after 16 h and peaked
after 24 h. Time course studies beyond this point were hardly feasible because of
the rapidly declining viability of the cells (<20% after 48 h of culture) . Our further
observation that the addition of cycloheximide to the cultures entirely abrogated
the inductive capacities of the cytokines used either alone or in combination, shows
that the cytokine-induced CD23 expression on LC is due to the synthesis of this
antigen rather than due to unhiding of preformed moieties.
As opposed to hrIL-4 and hrIFN-y, hrIL-2 (100 and 200 U/ml) and PMA failed
to induce CD23 antigens on any epidermal cell. Comparative studies with U937
cells which are known to constitutively exhibit FceR2/CD23 revealed a mean base-
line expression of CD23 expression on 17 t 4% of the cells and an increase of the
expression after 24 h of culture with either hrIL-4 (58 ± 10%) or hrIFN-y (49 ±
8%). While IL-2 was again ineffective in CD23 induction, PMA, in contrast to LC,
greatly upregulated CD23 expression (90 ± 5°Io of cells) .
FceR2/CD23+ LC Bind IgE Molecules.
￿
To see if the FceR2/CD23+ LC were able
to bind IgE molecules, LC-enriched epidermal cells that had been stimulated with
1,000 U/ml of both hrIL-4 and hrIFN-y were successively incubated with myeloma
IgE and anti-IgE/FITC and then analyzed by flow cytometry. These experiments
revealed a positive staining of 23 ± 4°/ of the LC (Fig. 1). This percentage was
less than that obtained by flow cytometry with the anti-CD23 reagent (40 ± 6%)
and probably due to the low affinity of the receptor. When preincubation with M-
L25 was followed by myeloma IgE, no IgE binding could be demonstrated on cul-
tured LC-enriched epidermal cells or U937 cells.
Discussion
In this study, we have shown that (a) freshly isolated human epidermal cell from
nonatopic donors greatly enriched for CDla+ LC fail to react with anti-CD23 mAb
as assessed by indirect immunofluorescence and rosette assays, respectively; (b) a
percentage of the LC exhibit anti-FceR2/CD23 reactivity when cultured for 24 h
in the presence of hrIL-4 and/or hrIFN-y, but not when cultured in the presence
of hrIL-2, PMA, or culture medium alone, and that this hrIL-4/hrIFN-y-induced
emergence of anti-FceR2/CD23 immunolabeling ofLC can be prevented by adding
cycloheximide to the culture media; (c) a considerable percentage of LC when cul-BIEBER ET AL.
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tured in the presence of hrIL-4/hrIFN--y, but not when cultured in media alone,
bind IgE molecules and that this binding can be prevented by preincubation of the
cells with anti-FcER2/CD23 mAb.
The key observation made in this study, i.e., the triggering ofanti-FceR2/CD23 moie-
ties on LC by hrIL-4/hrIFN-y, can be either explained by the induction of biosynthesis
of these structures, or alternatively, by the unmasking or exocytosis of preformed pro-
teins. The prevention ofthe cytokine-induced appearance of anti-FceR2/CD23-reactive
LC by cycloheximide proved the validity of the former assumption. Epidermal cell sus-
pensions used in our study were greatly enriched for LC, but still contained a large number
of keratinocytes, a putative source of cytokines (15). The cytokine-driven synthesis of
anti-FceR2/CD23-reactive structures by LC may therefore either be due to a direct effect
of hrIL-4/rhIFN-y on LC, or alternatively, due to keratinocyte activation by these cytokines
leading to the production/release of other mediators responsible for the observed
phenomenon.
In many cell types investigated, pronounced differences exist between hrIL-4 and
hrIFN-y in their capacity to modulate FceR2/CD23 expression (6-8). One of the few
cell types exhibiting reaction patterns to these cytokines similar to LC, i.e., upregulation
of anti-FceR2/CD23-reactive structures by both hrIL-4 and hrIFN-y, is the monoblastic
cell line U937 (14; this study). In view of the limited availability of purified human LC,
this cell line may thus serve as a useful model to study the molecular mechanisms under-
lying this phenomenon. Limitations in cell number are also the reason why we were
not able to characterize the exact molecular configuration ofanti-FcER2/CD23-reactive
moieties (16) on hrIL-4/hrIFN-y-stimulated LC . However, we strongly feel that these
antibody-reactive structures actually represent functional FceR2, as evidenced by the
IgE-binding capacity of hrIL-4/hrIFN--y-stimulated LC and its inhibition by the M-L25
or 3-5 reagent.
Although data presented in this study suggest that secretory products of either cir-
culating or infiltrating T cells are responsible for the in vivo induction ofFceR2 in atopic
dermatitis patients, the possibility still exists that functional alterations of resident skin
cells contribute to the occurrence of this event. In this context it should be noted that
anti-IgE+ LC have not been detected in noneczematous atopic patients (1, 2). This
may indicate that the presence of FceR2-bound IgE molecules on LC surfaces in
atopic dermatitis patients is not simply a functionally irrelevant bystander phenomenon
of atopy itself but is rather involved in the pathogenesis of the eczematous process.
The experimental model presented in this study will allow us to investigate the
molecular aspects of native IgE or IgE-antigen complexes binding to LC-FceR2,
as well as the effects of this interaction on the function of this cell type.
Summary
Human rIL-4 and human rIFN-y are able to induce the expression of the low affinity
receptor for IgE (FceR2/CD23) on normal human epidermal Langerhans cells, whereas
IL-2 and PMA have no effect. A synergistic effect is observed when both cytokines are
combined. These receptors are synthesized de novo by the LC since cycloheximide com-
pletely inhibits the appearance of FceR2/CD23. FceR2/CD23+ LC may have a major
role in the pathogenesis ofatopic eczema, as well as in the regulation of IgE synthesis.
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